Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 1:530:94-98.
doi: 10.1016/j.cca.2022.03.014. Epub 2022 Mar 16.

Tracking SARS-CoV-2 variants by entire S-gene analysis using long-range RT-PCR and Sanger sequencing

Mirai Matsubara  1 , Yuri Imaizumi  1 , Tatsuki Fujikawa  1 , Takayuki Ishige  2 , Motoi Nishimura  1 , Akiko Miyabe  1 , Shota Murata  1 , Kenji Kawasaki  1 , Toshibumi Taniguchi  3 , Hidetoshi Igari  3 , Kazuyuki Matsushita  1
Affiliations

Tracking SARS-CoV-2 variants by entire S-gene analysis using long-range RT-PCR and Sanger sequencing

Mirai Matsubara et al. Clin Chim Acta. .

Abstract

Introduction: Genomic surveillance of the SARS-CoV-2 virus is important to assess transmissibility, disease severity, and vaccine effectiveness. The SARS-CoV-2 genome consists of approximately 30 kb single-stranded RNA that is too large to analyze the whole genome by Sanger sequencing. Thus, in this study, we performed Sanger sequencing following long-range RT-PCR of the entire SARS-CoV-2 S-gene and analyzed the mutational dynamics.

Methods: The 4 kb region, including the S-gene, was amplified by two-step long-range RT-PCR. Then, the entire S-gene sequence was determined by Sanger sequencing. The amino acid mutations were identified as compared with the reference SARS-CoV-2 genome.

Results: The S:D614G mutation was found in all samples. The R.1 variants were detected after January 2021. Alpha variants started to emerge in April 2021. Delta variants replaced Alpha in July 2021. Then, Omicron variants were detected after December 2021. These mutational dynamics in samples collected in the Chiba University Hospital were similar to those in Japan.

Conclusion: The emergence of variants of concern (VOC) has been reported by the entire S-gene analysis. As the VOCs have unique mutational patterns of the S-gene region, analysis of the entire S-gene will be useful for molecular surveillance of the SARS-CoV-2 in clinical laboratories.

Keywords: Long-range RT-PCR; S-gene; SARS-CoV-2; Sanger sequencing; Surveillance.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Method overview of the long-range RT-PCR followed by Sanger sequencing. The SARS-CoV-2 genome consists of 29,903 bases (blue line). The S-gene is encoded 21,563–25,384 position of the genome (blue box). “RT-PCR,” dotted line and solid lines indicate first-strand cDNA and following PCR amplification region, respectively. Sequencing, dashed lines indicate sequencing regions. Triangles indicate primer binding sites.
Fig. 2
Fig. 2
Correlations of viral RNA concentration, the success rate of sequencing, and the Cq values of long-range RT-PCR. (A) viral RNA concentration vs. success rate of sequencing. Quartile groups: Q1 (≤3.0 log10 copies/uL), Q2 (>3.0–≤4.0 log10 copies/uL), Q3 (>4.0–≤5.0 log10 copies/uL), and Q4 (>5.0 log10 copies/uL). The success rate of sequencing: Q1, 68% (27/40); Q2, 81% (39/48); Q3, 94% (46/49); and Q4, 100% (46/46). (B) viral RNA concentration vs. Cq values of long-range RT-PCR. The Cq values of long-range RT-PCR were negatively correlated with viral RNA concentration. The p-value was determined by Spearman rank-order correlation test.
Fig. 3
Fig. 3
The mutational pattern of spike protein among the frequently observed SARS-CoV-2 variants in Japan.
Fig. 4
Fig. 4
Tracking SARS-CoV-2 variants by the spike protein mutation. “Undetermined” includes various lineages of SARS-CoV-2 which could not be determined the lineages because of the lack of specific mutation patterns except for S:D614G.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO), WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int, 2021 (accessed 16 December 2021).
    1. Volz E., Mishra S., Chand M., Barrett J.C., Johnson R., Geidelberg L., Hinsley W.R., Laydon D.J., Dabrera G., O’Toole Á., Amato R., Ragonnet-Cronin M., Harrison I., Jackson B., Ariani C.V., Boyd O., Loman N.J., McCrone J.T., Gonçalves S., Jorgensen D., Myers R., Hill V., Jackson D.K., Gaythorpe K., Groves N., Sillitoe J., Kwiatkowski D.P., Flaxman S., Ratmann O., Bhatt S., Hopkins S., Gandy A., Rambaut A., Ferguson N.M. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266–269. - PubMed
    1. Singh J., Rahman S.A., Ehtesham N.Z., Hira S., Hasnain S.E. SARS-CoV-2 variants of concern are emerging in India. Nat. Med. 2021;27:1131–1133. - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck R.W., Jr, Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U., Gruber W.C. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., McGettigan J., Khetan S., Segall N., Solis J., Brosz A., Fierro C., Schwartz H., Neuzil K., Corey L., Gilbert P., Janes H., Follmann D., Marovich M., Mascola J., Polakowski L., Ledgerwood J., Graham B.S., Bennett H., Pajon R., Knightly C., Leav B., Deng W., Zhou H., Han S., Ivarsson M., Miller J., Zaks T., COVE Study Group Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. - PMC - PubMed

Supplementary concepts